A Tumor-specific MicroRNA Recognition System Facilitates the Accurate Targeting to Tumor Cells by Magnetic Nanoparticles

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e318-

  Yu, Yingting ^a   Yao, Yi ^a   Yan, Hao ^b   Wang, Rui ^a   Zhang, Zhenming ^a   Sun, Xiaodan ^b   Zhao, Lingyun ^b   Ao, Xiang ^a   Xie, Zhen ^a,c   Wu, Qiong ^a  

^a Tsinghua University   (China)

^b Ministry of Education   (China)

^c TSINGHUA NATIONAL LABORATORY FOR INFORMATION SCIENCE AND TECHNOLOGY   (China)

Author keywords

in vivo cancer therapy; magnetic nanoparticles; microRNA recognition system; tumor specific

Indexed keywords

MAGNETIC NANOPARTICLE; MICRORNA; MICRORNA 145; MICRORNA 21; MICRORNA 9; NANOCARRIER; POLYETHYLENEIMINE; REPETITIVE DNA; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM CELL; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SPECIFICITY; FEMALE; FLUORESCENCE; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CELL; MCF 7 CELL LINE; METASTASIS; MICRORNA RECOGNITION SYSTEM; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMID; PRIORITY JOURNAL; REPORTER GENE; REPRESSOR GENE; TET ACTIVATOR GENE; TUMOR LOCALIZATION;

EID: 84965171255     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.28     Document Type: Article

References (75)

1. Siegel, R, Naishadham, D and Jemal, A (2012). Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Racioppi, M, D'Agostino, D, Totaro, A, Pinto, F, Sacco, E, D'Addessi, A et al. (2012). Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int 88: 249-258.
3. Marta, GN, Hanna, SA, Gadia, R, Correa, SF, Silva, JL and Carvalho, Hde A (2012). The role of radiotherapy in urinary bladder cancer: current status. Int Braz J Urol 38: 144-53; discussion 153.
4. Zhang, L, Fan, Y and Wu, Y (2014). Inositol based non-viral vectors for transgene expression in human cervical carcinoma and hepatoma cell lines. Biomaterials 35: 2039-2050.
5. Park, H, Tsutsumi, H and Mihara, H (2013). Cell penetration and cell-selective drug delivery using α-helix peptides conjugated with gold nanoparticles. Biomaterials 34: 4872-4879.
6. Wirth T and Ylä-Herttuala S. Gene therapy used in cancer treatment. Biomedicines 2014, 2: 149-162.
7. Unger, FT, Witte, I and David, KA (2015). Prediction of individual response to anticancer therapy: historical and future perspectives. Cell Mol Life Sci 72: 729-757.
8. Iorio, MV, Ferracin, M, Liu, CG, Veronese, A, Spizzo, R, Sabbioni, S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
9. Yanaihara, N, Caplen, N, Bowman, E, Seike, M, Kumamoto, K, Yi, M et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
10. Schetter, AJ, Leung, SY, Sohn, JJ, Zanetti, KA, Bowman, ED, Yanaihara, N et al. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436.
11. He, L and Hannon, GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
12. Lu, J, Getz, G, Miska, EA, Alvarez-Saavedra, E, Lamb, J, Peck, D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
13. Zhang, Z, Li, Z, Gao, C, Chen, P, Chen, J, Liu, W et al. (2008). miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88: 1358-1366.
14. Si, ML, Zhu, S, Wu, H, Lu, Z, Wu, F and Mo, YY (2007). miR-21-mediated tumor growth. Oncogene 26: 2799-2803.
15. Medina, PP, Nolde, M and Slack, FJ (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86-90.
16. Esquela-Kerscher, A and Slack, FJ (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
17. Calin, GA and Croce, CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
18. Zhang, B, Pan, X, Cobb, GP and Anderson, TA (2007). MicroRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12.
19. Ferracin, M, Veronese, A and Negrini, M (2010). Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 10: 297-308.
20. Mansfield, JH, Harfe, BD, Nissen, R, Obenauer, J, Srineel, J, Chaudhuri, A et al. (2004). MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nat Genet 36: 1079-1083.
21. Brown, BD, Gentner, B, Cantore, A, Colleoni, S, Amendola, M, Zingale, A et al. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467.
22. Wu, C, Lin, J, Hong, M, Choudhury, Y, Balani, P, Leung, D et al. (2009). Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy. Mol Ther 17: 2058-2066.
23. Lee, CY, Rennie, PS and Jia, WW (2009). MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 15: 5126-5135.
24. Xie, Z, Wroblewska, L, Prochazka, L, Weiss, R and Benenson, Y (2011). Multi-input RNAibased logic circuit for identification of specific cancer cells. Science 333: 1307-1311.
25. Kesharwani, P, Gajbhiye, V and Jain, NK (2012). A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33: 7138-7150.
26. Oh, IH, Min, HS, Li, L, Tran, TH, Lee, YK, Kwon, IC et al. (2013). Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials 34: 6454-6463.
27. Kim, HA, Nam, K and Kim, SW (2014). Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 35: 7543-7552.
28. Yoshizaki, Y, Yuba, E, Sakaguchi, N, Koiwai, K, Harada, A and Kono, K (2014). Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy. Biomaterials 35: 8186-8196.
29. Matsumura, Y and Maeda, H (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392.
30. Alexis, F, Pridgen, E, Molnar, LK and Farokhzad, OC (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-515.
31. Lin, G, Zhu, W, Yang, L, Wu, J, Lin, B, Xu, Y et al. (2014). Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells. Biomaterials 35: 9495-9507.
32. Huang, KW, Chieh, JJ, Horng, HE, Hong, CY and Yang, HC (2012). Characteristics of magnetic labeling on liver tumors with anti-alpha-fetoprotein-mediated Fe3O4 magnetic nanoparticles. Int J Nanomedicine 7: 2987-2996.
33. Huang, J, Bu, L, Xie, J, Chen, K, Cheng, Z, Li, X et al. (2010). Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 4: 7151-7160.
34. Colombo, M, Carregal-Romero, S, Casula, MF, Gutiérrez, L, Morales, MP, Böhm, IB et al. (2012). Biological applications of magnetic nanoparticles. Chem Soc Rev 41: 4306-4334.
35. Ren, Y, Zhang, H, Chen, B, Cheng, J, Cai, X, Liu, R et al. (2012). Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine 7: 2261-2269.
36. Jain, TK, Morales, MA, Sahoo, SK, Leslie-Pelecky, DL and Labhasetwar, V (2005). Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2: 194-205.
37. Yiu, HH, Pickard, MR, Olariu, CI, Williams, SR, Chari, DM and Rosseinsky, MJ (2012). Fe3O4-PEI-RITC magnetic nanoparticles with imaging and gene transfer capability: development of a tool for neural cell transplantation therapies. Pharm Res 29: 1328-1343.
38. McBain, SC, Yiu, HH and Dobson, J (2008). Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 3: 169-180.
39. Yiu HHP, McBain SC, El Haj AJ, Dobson J. A triple-layer design for polyethyleneiminecoated, nanostructured magnetic particles and their use in DNA binding and transfection. Nanotechnology 2007; 18: 435601.
40. Kasturi, SP, Sachaphibulkij, K and Roy, K (2005). Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 26: 6375-6385.
41. Yamano, S, Dai, J, Hanatani, S, Haku, K, Yamanaka, T, Ishioka, M et al. (2014). Long-term efficient gene delivery using polyethylenimine with modified Tat peptide. Biomaterials 35: 1705-1715.
42. Liu, C, Liu, F, Feng, L, Li, M, Zhang, J and Zhang, N (2013). The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 34: 2547-2564.
43. Zhu, S, Si, ML, Wu, H and Mo, YY (2007). MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336.
44. Frankel, LB, Christoffersen, NR, Jacobsen, A, Lindow, M, Krogh, A and Lund, AH (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033.
45. Seike, M, Goto, A, Okano, T, Bowman, ED, Schetter, AJ, Horikawa, I et al. (2009). MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 106: 12085-12090.
46. Slaby, O, Svoboda, M, Fabian, P, Smerdova, T, Knoflickova, D, Bednarikova, M et al. (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402.
47. Ma, L, Young, J, Prabhala, H, Pan, E, Mestdagh, P, Muth, D et al. (2010). miR-9, a MYC/ MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
48. Yao, Y, Jin, S, Long, H, Yu, Y, Zhang, Z, Cheng, G, et al. (2015). RNAe: an effective method for targeted protein translation enhancement by artificial non-coding RNA with SINEB2 repeat. Nucleic Acids Res (in press).
49. Yan, H, Chen, Y, Sun, XD, Zhao, LY, Zhang, CX, Bian, L, et al. One-pot synthesis of size and structure-controllable Fe3O4 spheres with a high saturation magnetization as contrast agents for T2 magnetic resonance imaging. Small (submitted).
50. Meng, F, Henson, R, Wehbe-Janek, H, Ghoshal, K, Jacob, ST and Patel, T (2007 MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
51. Benjamin T, Lucie Z, Scott M, Kim F, Christophe B, Hans JG. Electrostatic self-assembly of PEG copolymers onto porous silica nanoparticles. Langmuir 2008; 24: 8143-8150.
52. Shi, B, Sepp-Lorenzino, L, Prisco, M, Linsley, P, deAngelis, T and Baserga, R (2007). Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590.
53. Ostenfeld, MS, Bramsen, JB, Lamy, P, Villadsen, SB, Fristrup, N, Sørensen, KD et al. (2010). miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29: 1073-1084.
54. Sangyong J, Jiehyun S, Ali K, Thanh-Nga TT, Paul EL, Robert L. Construction of nonbiofouling surfaces by polymeric self-assembled monolayers. Langmuir 19: 9989-9993.
55. Shingara, J, Keiger, K, Shelton, J, Laosinchai-Wolf, W, Powers, P, Conrad, R et al. (2005). An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 11: 1461-1470.
56. Bai, YN, Yu, ZY, Luo, LX, Yi, J, Xia, QJ, Zeng, Y (2014). MicroRNA-21 accelerates hepatocyte proliferation in vitro via PI3K/Akt signaling by targeting PTEN. Biochem Bioph Res Co 443: 802-807.
57. Khew-Goodall, Y and Goodall, GJ (2010). Myc-modulated miR-9 makes more metastases. Nat Cell Biol 12: 209-211.
58. Zhu, L, Chen, H, Zhou, D, Li, D, Bai, R, Zheng, S et al. (2012). MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 29: 1037-1043.
59. Li, J, Yao, B, Huang, H, Wang, Z, Sun, C, Fan, Y et al. (2009). Real-time polymerase chain reaction microRNA detection based on enzymatic stem-loop probes ligation. Anal Chem 81: 5446-5451.
60. Yang, H, Hui, A, Pampalakis, G, Soleymani, L, Liu, FF, Sargent, EH et al. (2009). Direct, electronic microRNA detection for the rapid determination of differential expression profiles. Angew Chem Int Ed Engl 48: 8461-8464.
61. Rinaudo, K, Bleris, L, Maddamsetti, R, Subramanian, S, Weiss, R and Benenson, Y (2007). A universal RNAi-based logic evaluator that operates in mammalian cells. Nat Biotechnol 25: 795-801.
62. Levine, AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
63. Antonia, SJ, Mirza, N, Fricke, I, Chiappori, A, Thompson, P, Williams, N et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878-887.
64. Suzuki K and Matsubara H (2011). Recent advances in p53 research and cancer treatment. BioMed Res Int (article ID 978312, 7 pages).
65. Bourdon, JC (2007). p53 and its isoforms in cancer. Br J Cancer 97: 277-282.
66. Alizadeh, AA, Eisen, MB, Davis, RE, Ma, C, Lossos, IS, Rosenwald, A et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
67. Golub, TR, Slonim, DK, Tamayo, P, Huard, C, Gaasenbeek, M, Mesirov, JP et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
68. Dörr, JR, Yu, Y, Milanovic, M, Beuster, G, Zasada, C, Däbritz, JH et al. (2013). Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501: 421-425.
69. You, M, Zhu, G, Chen, T, Donovan, MJ and Tan, W (2015). Programmable and multiparameter DNA-based logic platform for cancer recognition and targeted therapy. J Am Chem Soc 137: 667-674.
70. Morille, M, Passirani, C, Vonarbourg, A, Clavreul, A and Benoit, JP (2008). Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29: 3477-3496.
71. Xia, T, Kovochich, M, Liong, M, Meng, H, Kabehie, S, George, S et al. (2009). Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3: 3273-3286.
72. Kievit, FM, Veiseh, O, Bhattarai, N, Fang, C, Gunn, JW, Lee, D et al. (2009). PEI-PEGchitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 19: 2244-2251.
73. Zhu, L, Ma, J, Jia, N, Zhao, Y and Shen, H (2009). Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces 68: 1-6.
74. Jokerst, JV, Lobovkina, T, Zare, RN and Gambhir, SS (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 6: 715-728.
75. Yao, Y, He, Y, Guan, Q and Wu, Q (2014). A tetracycline expression system in combination with Sox9 for cartilage tissue engineering. Biomaterials 35: 1898-1906.